News

Public · Published

Coinbase says 'jurisdictional overlap' is blocking U.S. equity perps – Here's what it means

Coinbase stated that 'jurisdictional overlap' is preventing the launch of U.S. equity perpetual futures, which are contracts allowing bets on price moves without owning the stock. Meanwhile, real-world asset perps have grown fourfold in 2026, and U.S. regulatory approval could speed this growth.

Published:

Updated:

What happened

Coinbase stated that 'jurisdictional overlap' is preventing the launch of U.S. equity perpetual futures, which are contracts allowing bets on price moves without owning the stock. Meanwhile, real-world asset perps have grown fourfold in 2026, and U.S. regulatory approval could speed this growth.

Confirmed

Global impact / market context

If regulators resolve the overlap, Coinbase could offer new products, boosting trading revenue. For investors, this means more ways to bet on stocks with borrowed money, but also higher risk. Approval might also encourage other exchanges to enter, increasing competition and innovation.

Analyst inference

The fourfold surge in real-world asset perps shows strong demand for tokenized assets. U.S. approval could set a precedent, attracting more capital and legitimizing these products. This might pressure traditional exchanges to adapt, while investors gain new exposure to assets like bonds or commodities through crypto platforms.

Analyst inference

What to watch

  1. Watch for any official statements from U.S. regulators like the SEC or CFTC about resolving jurisdictional overlap, as Coinbase's ability to offer equity perps depends on their decision. Confirmed
  2. Investors should monitor Coinbase's next earnings call for updates on product launches, as management may discuss progress or hurdles in getting regulatory approval for equity perps. Proposed
  3. If approval happens, expect increased trading volume in real-world asset perps, which could boost Coinbase's revenue and attract more institutional investors seeking diversified crypto-based products. Analyst inference

Evidence